Ignite Creation Date:
2025-12-26 @ 10:34 AM
Ignite Modification Date:
2025-12-26 @ 10:34 AM
Study NCT ID:
NCT05495828
Status:
UNKNOWN
Last Update Posted:
2023-10-26
First Post:
2022-08-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Sponsor:
Peking University People's Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-12-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-03-10
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-09
First Submit QC Date:
None
Study First Post Date:
2022-08-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-24
Last Update Post Date:
2023-10-26
Last Update Post Date Type:
ACTUAL